Daiichi Sankyo Company, Limited

Tokyo Stock Exchange:4568.T

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

Location

Japan

Market Cap

USD 42.42 B

Share Price

USD 22.78

Avg Daily Volume

6,469,921

Change (1 day)

-0.29%

Change (1 year)

-33.49%

Change (YTD)

-17.86%

Daiichi Sankyo Company, Limited Enterprise Value to EBITDA (EV/EBITDA) on June 27, 2025: 13.40

Daiichi Sankyo Company, Limited Enterprise Value to EBITDA (EV/EBITDA) is 13.40 on June 27, 2025, a -54.92% change year over year. EV/EBITDA ratio compares the enterprise value to the EBITDA; lower suggests more favorable company valuation.

Daiichi Sankyo Company, Limited 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 37.19 on June 27, 2025, which is 177.53% above the current Enterprise Value to EBITDA (EV/EBITDA).
Daiichi Sankyo Company, Limited 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 12.59 on June 27, 2025, which is -6.08% below the current Enterprise Value to EBITDA (EV/EBITDA).
Daiichi Sankyo Company, Limited average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is 23.84.

Daily

From:

To:

Zoom:

Key data

Date	Enterprise Value to EBITDA (EV/EBITDA)	Free Cash Flow Yield	Dividend Yield	Market Capitalization

Tokyo Stock Exchange: 4568.T

Daiichi Sankyo Company, Limited

CEO	Mr. Hiroyuki Okuzawa
IPO Date	Jan. 4, 2000
Location	Japan
Headquarters	3-5-1, Nihonbashi-honcho
Employees	18,726
Sector	🏥 Health Care
Industries Pharmaceuticals 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies

Description

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.